Drug Information

Drug (ID: DG01706) and It's Reported Resistant Information
Name
AGI-5198/Talazoparib
Synonyms
AGI-5198/Talazoparib
    Click to Show/Hide
Drug Resistance Disease(s)
Disease(s) with Clinically Reported Resistance for This Drug (2 diseases)
Sarcoma [ICD-11: 2C35]
[1]
Solid tumour/cancer [ICD-11: 2A00-2F9Z]
[1]
Type(s) of Resistant Mechanism of This Drug
  EADR: Epigenetic Alteration of DNA, RNA or Protein
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-02: Benign/in-situ/malignant neoplasm
Click to Show/Hide the Resistance Disease of This Class
Solid tumour/cancer [ICD-11: 2A00-2F9Z]
Click to Show/Hide
Drug Resistance Data Categorized by Their Corresponding Mechanisms
  Epigenetic Alteration of DNA, RNA or Protein (EADR) Click to Show/Hide
Key Molecule: Oxalosuccinate decarboxylase (IDH1) [1]
Resistant Disease Solid tumour/cancer [ICD-11: 2A00-2F9Z]
 Disease Info 
Molecule Alteration Missense mutation
p.R132H (c.395G>A)
 Molecule Info 
Wild Type Structure Method: X-ray diffraction Resolution: 1.65  Å
PDB: 6BKX
Mutant Type Structure Method: X-ray diffraction Resolution: 1.88  Å
PDB: 4UMX
   Download The Information of Sequence       Download The Structure File   
RMSD: 3.46
TM score: 0.85834
Amino acid change:
R132H
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
M
M
S
S
K
K
K
K
I
I
S
S
G
G
G
G
S
S
10
|
V
V
V
V
E
E
M
M
Q
Q
G
G
D
D
E
E
M
M
T
T
20
|
R
R
I
I
I
I
W
W
E
E
L
L
I
I
K
K
E
E
K
K
30
|
L
L
I
I
F
F
P
P
Y
Y
V
V
E
E
L
L
D
D
L
L
40
|
H
H
S
S
Y
Y
D
D
L
L
G
G
I
I
E
E
N
N
R
R
50
|
D
D
A
A
T
T
N
N
D
D
Q
Q
V
V
T
T
K
K
D
D
60
|
A
A
A
A
E
E
A
A
I
I
K
K
K
K
H
H
N
N
V
V
70
|
G
G
V
V
K
K
C
C
A
A
T
T
I
I
T
T
P
P
D
D
80
|
E
E
K
K
R
R
V
V
E
E
E
E
F
F
K
K
L
L
K
K
90
|
Q
Q
M
M
W
W
K
K
S
S
P
P
N
N
G
G
T
T
I
I
100
|
R
R
N
N
I
I
L
L
G
G
G
G
T
T
V
V
F
F
R
R
110
|
E
E
A
A
I
I
I
I
C
C
K
K
N
N
I
I
P
P
R
R
120
|
L
L
V
V
S
S
G
G
W
W
V
V
K
K
P
P
I
I
I
I
130
|
I
I
G
G
R
H
H
H
A
A
Y
Y
G
G
D
D
Q
Q
Y
Y
140
|
R
R
A
A
T
T
D
D
F
F
V
V
V
V
P
P
G
G
P
P
150
|
G
G
K
K
V
V
E
E
I
I
T
T
Y
Y
T
T
P
P
S
S
160
|
D
D
G
G
T
T
Q
Q
K
K
V
V
T
T
Y
Y
L
L
V
V
170
|
H
H
N
N
F
F
E
E
E
E
G
G
G
G
G
G
V
V
A
A
180
|
M
M
G
G
M
M
Y
Y
N
N
Q
Q
D
D
K
K
S
S
I
I
190
|
E
E
D
D
F
F
A
A
H
H
S
S
S
S
F
F
Q
Q
M
M
200
|
A
A
L
L
S
S
K
K
G
G
W
W
P
P
L
L
Y
Y
L
L
210
|
S
S
T
T
K
K
N
N
T
T
I
I
L
L
K
K
K
K
Y
Y
220
|
D
D
G
G
R
R
F
F
K
K
D
D
I
I
F
F
Q
Q
E
E
230
|
I
I
Y
Y
D
D
K
K
Q
Q
Y
Y
K
K
S
S
Q
Q
F
F
240
|
E
E
A
A
Q
Q
K
K
I
I
W
W
Y
Y
E
E
H
H
R
R
250
|
L
L
I
I
D
D
D
D
M
M
V
V
A
A
Q
Q
A
A
M
M
260
|
K
K
S
S
E
E
G
G
G
G
F
F
I
I
W
W
A
A
C
C
270
|
K
K
N
N
Y
Y
D
D
G
G
D
D
V
V
Q
Q
S
S
D
D
280
|
S
S
V
V
A
A
Q
Q
G
G
Y
Y
G
G
S
S
L
L
G
G
290
|
M
M
M
M
T
T
S
S
V
V
L
L
V
V
C
C
P
P
D
D
300
|
G
G
K
K
T
T
V
V
E
E
A
A
E
E
A
A
A
A
H
H
310
|
G
G
T
T
V
V
T
T
R
R
H
H
Y
Y
R
R
M
M
Y
Y
320
|
Q
Q
K
K
G
G
Q
Q
E
E
T
T
S
S
T
T
N
N
P
P
330
|
I
I
A
A
S
S
I
I
F
F
A
A
W
W
T
T
R
R
G
G
340
|
L
L
A
A
H
H
R
R
A
A
K
K
L
L
D
D
N
N
N
N
350
|
K
K
E
E
L
L
A
A
F
F
F
F
A
A
N
N
A
A
L
L
360
|
E
E
E
E
V
V
S
S
I
I
E
E
T
T
I
I
E
E
A
A
370
|
G
G
F
F
M
M
T
T
K
K
D
D
L
L
A
A
A
A
C
C
380
|
I
I
K
K
G
G
L
L
P
P
N
N
V
V
Q
Q
R
R
S
S
390
|
D
D
Y
Y
L
L
N
N
T
T
F
F
E
E
F
F
M
M
D
D
400
|
K
K
L
L
G
G
E
E
N
N
L
L
K
K
I
I
K
K
L
L
410
|
A
A
Q
Q
A
A
K
K
L
L
S
S
L
L
E
E
H
H
H
H
420
|
H
H
H
H
H
H
H
H
H
H
H
H
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
In Vitro Model IDH2 cells Ovary Homo sapiens (Human) CVCL_D3DY
IDH1 cells Ovary Homo sapiens (Human) CVCL_D3DY
In Vivo Model Female athymic nu/nu mouse PDX model Mus musculus
Experiment for
Drug Resistance		 Promega assay
Mechanism Description The oncometabolite, 2-hydroxyglutarate, renders IDH1/2 mutant cancer cells deficient in homologous recombination and confers vulnerability to synthetic lethal targeting with PARP inhibitors.
Sarcoma [ICD-11: 2C35]
Click to Show/Hide
Drug Resistance Data Categorized by Their Corresponding Mechanisms
  Epigenetic Alteration of DNA, RNA or Protein (EADR) Click to Show/Hide
Key Molecule: Oxalosuccinate decarboxylase (IDH1) [1]
Resistant Disease Sarcoma [ICD-11: 2C35.0]
 Disease Info 
Molecule Alteration Missense mutation
p.R132C (c.394C>T)
 Molecule Info 
Wild Type Structure Method: X-ray diffraction Resolution: 1.93  Å
PDB: 5GIR
Mutant Type Structure Method: X-ray diffraction Resolution: 2.20  Å
PDB: 6IO0
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.64
TM score: 0.30204
Amino acid change:
R132C
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
-
M
-
S
-
K
-
K
-
I
-
S
-
G
-
G
-
S
10
|
-
V
-
V
-
E
-
M
-
Q
-
G
-
D
-
E
-
M
-
T
20
|
-
R
-
I
-
I
-
W
-
E
-
L
-
I
-
K
-
E
-
K
30
|
-
L
-
I
-
F
-
P
-
Y
-
V
-
E
-
L
-
D
-
L
40
|
-
H
-
S
-
Y
-
D
-
L
-
G
-
I
-
E
-
N
-
R
50
|
-
D
-
A
-
T
-
N
-
D
-
Q
-
V
-
T
-
K
-
D
60
|
-
A
-
A
-
E
-
A
-
I
-
K
-
K
-
H
-
N
-
V
70
|
-
G
-
V
-
K
-
C
-
A
-
T
-
I
-
T
-
P
-
D
80
|
-
E
-
K
-
R
-
V
-
E
-
E
-
F
-
K
-
L
-
K
90
|
-
Q
-
M
-
W
-
K
-
S
-
P
-
N
-
G
-
T
-
I
100
|
-
R
-
N
-
I
-
L
-
G
-
G
-
T
-
V
-
F
-
R
110
|
-
E
-
A
-
I
-
I
-
C
-
K
-
N
-
I
-
P
-
R
120
|
-
L
-
V
-
S
-
G
-
W
-
V
K
K
P
P
I
I
I
I
130
|
I
I
G
G
S
C
H
H
A
A
Y
Y
G
G
D
D
-
Q
-
Y
140
|
-
R
-
A
-
T
-
D
-
F
-
V
-
V
-
P
-
G
-
P
150
|
-
G
-
K
-
V
-
E
-
I
-
T
-
Y
-
T
-
P
-
S
160
|
-
D
-
G
-
T
-
Q
-
K
-
V
-
T
-
Y
-
L
-
V
170
|
-
H
-
N
-
F
-
E
-
E
-
G
-
G
-
G
-
V
-
A
180
|
-
M
-
G
-
M
-
Y
-
N
-
Q
-
D
-
K
-
S
-
I
190
|
-
E
-
D
-
F
-
A
-
H
-
S
-
S
-
F
-
Q
-
M
200
|
-
A
-
L
-
S
-
K
-
G
-
W
-
P
-
L
-
Y
-
L
210
|
-
S
-
T
-
K
-
N
-
T
-
I
-
L
-
K
-
K
-
Y
220
|
-
D
-
G
-
R
-
F
-
K
-
D
-
I
-
F
-
Q
-
E
230
|
-
I
-
Y
-
D
-
K
-
Q
-
Y
-
K
-
S
-
Q
-
F
240
|
-
E
-
A
-
Q
-
K
-
I
-
W
-
Y
-
E
-
H
-
R
250
|
-
L
-
I
-
D
-
D
-
M
-
V
-
A
-
Q
-
A
-
M
260
|
-
K
-
S
-
E
-
G
-
G
-
F
-
I
-
W
-
A
-
C
270
|
-
K
-
N
-
Y
-
D
-
G
-
D
-
V
-
Q
-
S
-
D
280
|
-
S
-
V
-
A
-
Q
-
G
-
Y
-
G
-
S
-
L
-
G
290
|
-
M
-
M
-
T
-
S
-
V
-
L
-
V
-
C
-
P
-
D
300
|
-
G
-
K
-
T
-
V
-
E
-
A
-
E
-
A
-
A
-
H
310
|
-
G
-
T
-
V
-
T
-
R
-
H
-
Y
-
R
-
M
-
Y
320
|
-
Q
-
K
-
G
-
Q
-
E
-
T
-
S
-
T
-
N
-
P
330
|
-
I
-
A
-
S
-
I
-
F
-
A
-
W
-
T
-
R
-
G
340
|
-
L
-
A
-
H
-
R
-
A
-
K
-
L
-
D
-
N
-
N
350
|
-
K
-
E
-
L
-
A
-
F
-
F
-
A
-
N
-
A
-
L
360
|
-
E
-
E
-
V
-
S
-
I
-
E
-
T
-
I
-
E
-
A
370
|
-
G
-
F
-
M
-
T
-
K
-
D
-
L
-
A
-
A
-
C
380
|
-
I
-
K
-
G
-
L
-
P
-
N
-
V
-
Q
-
R
-
S
390
|
-
D
-
Y
-
L
-
N
-
T
-
F
-
E
-
F
-
M
-
D
400
|
-
K
-
L
-
G
-
E
-
N
-
L
-
K
-
I
-
K
-
L
410
|
-
A
-
Q
-
A
-
K
-
L
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
In Vitro Model IDH2 cells Ovary Homo sapiens (Human) CVCL_D3DY
IDH1 cells Ovary Homo sapiens (Human) CVCL_D3DY
In Vivo Model Female athymic nu/nu mouse PDX model Mus musculus
Experiment for
Drug Resistance		 Promega assay
Mechanism Description The oncometabolite, 2-hydroxyglutarate, renders IDH1/2 mutant cancer cells deficient in homologous recombination and confers vulnerability to synthetic lethal targeting with PARP inhibitors.
References
Ref 1 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivitySci Transl Med. 2017 Feb 1;9(375):eaal2463. doi: 10.1126/scitranslmed.aal2463.

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Yu.